High level contact group set up to address industry concerns over EU's REACH deadline

9 February 2010

A high level contact group has been set up to address European Union industry concerns about meeting the November 30, 2010, deadline under REACH for registration of chemicals that are produced in high volumes and/or are most hazardous.

The EU's REACH chemical legislation affects the drug industry, as it covers all substances for synthesis or processing used in the manufacture of pharmaceuticals.

According to the REACH Regulation, failure to register by the deadline means that a substance cannot be used or put on the market. The group, called the Directors' Contact Group, met for the first time on February 5 in Brussels. The group consists of director-level representatives from the European Commission, the European Chemicals Agency and from the industry associations CEFIC, Eurometaux, REACH Alliance, Concawe, FECC and UEAPME.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Generics